Skip to main content
Fig. 5 | Cancer & Metabolism

Fig. 5

From: A small-molecule pan-class I glucose transporter inhibitor reduces cancer cell proliferation in vitro and tumor growth in vivo by targeting glucose-based metabolism

Fig. 5

DRB18 inhibited the growth of A549 tumors xenografted in nude mice. A549 cells were subcutaneously implanted into the 4-week-old nude mice. Three days after implantation, mice were treated with DRB18 (10mg/kg) or vehicle, IP, three times per week. After 5 weeks of treatment, mice were euthanized and tumors removed. Values shown are mean ± SEM. *P < 0.05, **P ≤ 0.01, and ***P ≤ 0.001. a Images of surgically removed tumors. Top row represents tumors from vehicle-treated mice and bottom represents those from DRB18-treated mice. b Tumor volumes (mm3) after 5 weeks of treatment. c Tumor weights (g) after 5 weeks of treatment. d PLS-DA analysis of metabolites in comparison between vehicle and DRB18 treated tumors. e Metabolite set enrichment analysis for vehicle and DRB18 treated in A549 xenograft tumors. f Immunofluorescence analysis of hGLUT1-4 in vehicle and DRB18 treated tumors (n=4). Scale bar represents 100 microns

Back to article page

Cancer & Metabolism

ISSN: 2049-3002